RxDoctor Payments Data

Pradeep Selvaraj, MD

Internal Medicine · Woodville, MSNPI 1053545913

Payments from drug & device makers

$4,659in general payments, 2019–2025

Across 324 payments — averaging $14.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$871
  • Lilly USA, LLC$514
  • Boehringer Ingelheim$392
  • Pfizer$351
  • Sanofi-aventis U.S. LLC$292
  • plus $960 from 15 others

What the payments were for

  • Food & beverage$4,653100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,659 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$46,131
Medicare patients
100
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide255$332,574
JardianceEmpagliflozin331$270,602
OzempicSemaglutide159$197,681
JanuviaSitagliptin Phosphate220$170,434
LinzessLinaclotide225$160,021
EliquisApixaban173$136,160
RybelsusSemaglutide77$105,794
MounjaroTirzepatide65$102,922
FarxigaDapagliflozin Propanediol70$55,704
EntrestoSacubitril/Valsartan74$53,324
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$26,766
XareltoRivaroxaban37$24,607
Tresiba Flextouch U-200Insulin Degludec23$22,206
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$20,898
Breo ElliptaFluticasone/Vilanterol28$17,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$514$435,496320 claims
Novo NordiskOzempic, Rybelsus, Levemir$871$306,610247 claims
Boehringer IngelheimJardiance, Tradjenta$392$279,046342 claims
MerckJanuvia, Janumet$272$183,996237 claims
AbbVieLinzess$64$160,021225 claims
PfizerEliquis$351$136,160173 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,280$86,475110 claims
NovartisEntresto$103$53,32474 claims
Johnson & JohnsonXarelto$243$24,60737 claims
Sanofi-aventis U.S. LLCLantus$292$3,05218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Woodville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →